Company Registration No. 14894706 (England and Wales)
SL Biopharma Consultants Ltd
Unaudited accounts
for the period from 25 May 2023 to 31 May 2024
SL Biopharma Consultants Ltd
Unaudited accounts
Contents
SL Biopharma Consultants Ltd
Company Information
for the period from 25 May 2023 to 31 May 2024
Company Number
14894706 (England and Wales)
Registered Office
123 Cross Lane East
Gravesend
Kent
DA12 5HA
Accountants
King & Taylor
123 Cross Lane East
Gravesend
Kent
DA12 5HA
SL Biopharma Consultants Ltd
Statement of financial position
as at 31 May 2024
Creditors: amounts falling due within one year
(32,648)
Net current liabilities
(521)
Profit and loss account
444
For the period ending 31 May 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 25 February 2025 and were signed on its behalf by
S Lorimer
Director
Company Registration No. 14894706
SL Biopharma Consultants Ltd
Notes to the Accounts
for the period from 25 May 2023 to 31 May 2024
SL Biopharma Consultants Ltd is a private company, limited by shares, registered in England and Wales, registration number 14894706. The registered office is 123 Cross Lane East, Gravesend, Kent, DA12 5HA.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
20% straight line basis
4
Tangible fixed assets
Computer equipment
SL Biopharma Consultants Ltd
Notes to the Accounts
for the period from 25 May 2023 to 31 May 2024
Amounts falling due within one year
6
Creditors: amounts falling due within one year
2024
Taxes and social security
31,388
Brought
Forward
Advance/
credit
Repaid
Carried
Forward
Director
-
32,127
-
32,127
8
Average number of employees
During the period the average number of employees was 2.